Announcements
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
- Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
- Arbutus to Present at Jefferies London Healthcare Conference
More ▼
Key statistics
On Wednesday, Arbutus Biopharma Corp (0SGC:LSE) closed at 2.78, -15.45% below its 52-week high of 3.29, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.78 |
Average volume | 1.18k |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 535.96m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 20 minutes, as of May 08 2024 18:03 BST.
More ▼